vimarsana.com

Page 4 - மருந்து கட்டுப்பாடு அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covid-19: Solution Group to supply CanSino vaccine in Malaysia

FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS KUALA LUMPUR (Bernama): Solution Group Bhd’s (SGB) wholly-owned subsidiary, Solution Biologics Sdn Bhd (SolBio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19. In a statement, the group said the finished product agreement allows SolBio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia.

Vaccination rate in line with current situation | Daily Express Online

Published on: Thursday, July 29, 2021 By: Bernama Text Size: Kuala Lumpur: With Malaysia’s per capita vaccination rate now among the fastest in the world, the National Covid-19 Immunisation Programme (Pick) is seen as an important shield in the fight against the virus and in achieving the herd immunity in the country. Coordinating Minister for the immunisation programme, Khairy Jamaluddin (pic), when explaining the programme in the Dewan Rakyat Wednesday, said the percentage of the country’s population having received at least one dose of the Covid-19 had surpassed some developed countries, like Japan, Australia, South Korea and New Zealand.  He said the programme, involving an allocation of RM5.8 billion, initially targeted 80 per cent of the population to receive the vaccine by February next year, but had been brought earlier to December this year after taking into account the current development.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.